ArticlePharmacoEconomics - open2025
Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.
Article in PharmacoEconomics - open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIsocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT. This study aimed to estimate health state utilities for mIDH glioma over the full disease course.
methodVignettes were developed to describe states from post-initial resection with no immediate need for RT/CT through to RT/CT and palliative care after recurrence. These were developed on the basis of literature review, patient-reported outcomes data from a clinical trial and qualitative interviews with clinicians and patients. The health state vignettes were valued by members of the UK public using the EQ-5D-5L and time trade-off methods. Subsequently, the vignette-derived utilities were re-weighted with the utility data from a clinical trial to estimate health state utilities for CUA.
resultsHealth state utilities were similar following the initial resection for targeted therapy or active observation (0.74) but lower in later stages of disease. Mean utilities for receiving first- and second-line RT/CT ranged from 0.34 to 0.55. Mean utilities ranged from 0.21 to 0.42 for recovery after tumour resection following recurrence and from -0.05 to 0.14 for palliative care.
conclusionThis study estimates health state utilities in glioma from after the initial resection through to palliative care and suggests that new treatments capable of delaying time to disease recurrence and initiation of RT/CT could produce a net gain in quality of life for individuals with mIDH glioma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.